Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3786-3792

  Haufe, Sven ^a   Haas, Verena ^b,c   Utz, Wolfgang ^b   Birkenfeld, Andreas L ^b   Jeran, Stephanie ^b,c   Böhnke, Jana ^b,c   Mähler, Anja ^b,c   Luft, Friedrich C ^b,c   Schulz Menger, Jeanette ^b   Boschmann, Michael ^b,c   Jordan, Jens ^a   Engeli, Stefan ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ABDOMINAL FAT; ABDOMINAL SUBCUTANEOUS FAT; ADIPOSE TISSUE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY FAT DISTRIBUTION; BODY MASS; CALORIC INTAKE; CARBOHYDRATE INTAKE; FAT CONTENT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; INTRAHEPATIC FAT; LIVER METABOLISM; LOW CALORY DIET; MACRONUTRIENT; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; CONTROLLED STUDY; DIET THERAPY; LIVER; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

ADIPOSITY; ADULT; DIET, REDUCING; FEMALE; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIVER; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; SUBCUTANEOUS FAT, ABDOMINAL; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT LOSS;

EID: 84891874234     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0102     Document Type: Article

References (40)

1. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444:881-887
2. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008;134:1369- 1375
3. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-960
4. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009;106:15430-15435
5. Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased wholebody adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 2010;18:1510-1515
6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-1832
7. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54: 603-608
8. Saaristo T, Moilanen L, Korpi-Hyövälti E, et al. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care 2010;33:2146-2151
9. Elias MC, Parise ER, de Carvalho L, Szejnfeld D, Netto JP. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition 2010;26:1094- 1099
10. Pozzato C, Verduci E, Scaglioni S, et al. Liver fat change in obese children after a 1-year nutrition-behavior intervention. J Pediatr Gastroenterol Nutr 2010;51:331- 335
11. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011;53: 1504-1514
12. Sjöström CD, Peltonen M, Wedel H, Sjöström L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36:20-25
13. Larsen TM, Dalskov SM, van Baak M, et al.; Diet, Obesity, and Genes (Diogenes) Project. Diets with high or low protein content and glycemic index for weightloss maintenance. N Engl J Med 2010; 363:2102-2113
14. Haufe S, Engeli S, Budziarek P, et al. Cardiorespiratory fitness and insulin sensitivity in overweight or obese subjects may be linked through intrahepatic lipid content. Diabetes 2010;59:1640-1647
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
16. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007;30:89-94
17. Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 2007;297:969-977
18. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006;49:755-765
19. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes andmanagement of patients with diabetes and liver disease. Diabetes Care 2007;30:734-743
20. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013;43:51-64
21. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36:815-823
22. Klein S. The case of visceral fat: argument for the defense. J Clin Invest 2004;113: 1530-1532
23. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction [corrected in Gastroenterology 2009;137: 393]. Gastroenterology 2009;136:1552- 1560
24. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009;58:1281-1288
25. Schäfer S, Kantartzis K, Machann J, et al. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest 2007;37:535-543
26. Thomas EL, Brynes AE, Hamilton G, et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006;12:5813-5819
27. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012;55:1738-1745
28. van der Heijden GJ, Wang ZJ, Chu ZD, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity (Silver Spring) 2010;18: 384-390
29. Koska J, Stefan N, Permana PA, et al. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am J Clin Nutr 2008; 87:295-302
30. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148:852-871
31. Ebbeling CB, Swain JF, Feldman HA, et al. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA 2012;307:2627-2634
32. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, BoldtMD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351
33. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142:711-725, e6
34. Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009;50:1087-1093
35. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40: 1387-1395
36. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342
37. Fidler MC, Sanchez M, Raether B, et al.; BLOSSOM Clinical Trial Group. A oneyear randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-3077
38. Landers PS, Landers TL. Survival analysis of dropout patterns in dieting clinical trials. J Am Diet Assoc 2004;104:1586- 1588
39. Elobeid MA, Padilla MA, McVie T, et al. Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS ONE 2009;4:e6624
40. Johnson RK, Friedman AB, Harvey-Berino J, Gold BC, McKenzie D. Participation in a behavioral weight-loss program worsens the prevalence and severity of underreporting among obese and overweight women. J AmDiet Assoc 2005;105:1948- 1951